Pionera Breast Cancer (BC): Phase III Study of First-Line (1L) Giredestrant Vs. Fulvestrant, Both Combined with a Cyclin-Dependent Kinase 4/6 Inhibitor (cdk4/6i), in Patients (pts) with Estrogen Receptor-Positive (ER+), HER2-locally Advanced/metastatic BC (la/mbc) with Resistance to Prior Adjuvant (adj) Endocrine Therapy (ET)
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要